Twelve months clinical outcome after bioresorbable vascular scaffold implantation in patients with stable angina and acute coronary syndrome. Data from the Polish National Registry

Postepy w Kardiologii Interwencyjnej

Volumn 12, Issue 2, 2016, Pages 108-115

  Rzeszutko, Łukasz ^a   Siudak, Zbigniew ^a   Tokarek, Tomasz ^a   Plens, Krzysztof ^b   Włodarczak, Adrian ^c   Lekston, Andrzej ^d   Ochała, Andrzej ^d   Gil, Robert J ^e,f   Balak, Wojciech ^g   Dudek, Dariusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakow Cardiovascular Research Institute   (Poland)

^c Miedziowe Centrum Zdrowia SA   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e Central Hospital of the Internal Affairs and Administration Ministry   (Poland)

^f POLISH ACADEMY OF SCIENCES   (Poland)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Bifurcation; Calcified; Complex lesion; Stent; Tortuosity

Indexed keywords

ACUTE CORONARY SYNDROME; ARTICLE; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY CALCIFICATION; DISEASE SEVERITY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POLAND; RESTENOSIS; RETROSPECTIVE STUDY; REVASCULARIZATION; SAFETY; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

EID: 84969180609     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/aic.2016.59360     Document Type: Article

References (25)

1. Karabulut A, Demirci Y. Cutting balloon use may ease the optimal apposition of bioresorbable vascular scaffold in in-stent stenosis. Postep Kardiol Inter 2015; 11: 64-6.
2. Rama-Merchan JC, Mattesini A, Dall'Ara G, et al. Chronic total occlusion successfully treated with a bioresorbable everolimus-eluting vascular scaffold. Postep Kardiol Inter 2014; 10: 128-39.
3. Onuma Y, Serruys PW, Perkins LEL, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary arterymodel: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010; 122: 2288-300.
4. Bruining N, de Winter S, Roelandt JRTC, et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc Interv 2010; 3: 449-56.
5. Lesiak M, Araszkiewicz A. Leaving nothing behind: is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease? Postep Kardiol Inter 2014; 10: 283-98.
6. Dariusz Dudek D, Rzeszutko Ł, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn 2014; 124: 669-77.
7. Table IV. Clinical outcome, device-oriented composite endpoint and major adverse cardiovascular events after 12 months of observation in comparison between patients with and without bifurcation of target vessel. Follow-up was available in 468 patients. Total MACE number is not equal to added components. Several events may occur in 1 patients Parameter Bifurcation (n = 127) No bifurcation (n = 339) P-value DOCE 1 (0.79%) 8 (2.36%) 0.3 MACE 3 (2.36%) 11 (3.26%) 0.6 Death 1 (0.79%) 1 (0.29%) 0.5 MI 2 (1.57%) 6 (1.78%) 0.9 TLR with urgent PCI 0 (0.00%) 7 (2.07%) 0.1 TVR with urgent CABG 0 (0%) 0 (0%)-Stent thrombosis 0 (0.00%) 2 (0.59%) 0.4 Stent restenosis 0 (0.00%) 10 (2.96%) 0.051 CABG-coronary artery bypass grafting, DOCE-device-oriented composite endpoint, MACE-major adverse cardiovascular event, MI-myocardial infarction, PCI-percutaneous coronary interventions, TLR-target lesion revascularisation, TVR-target vessel revascularisation.
8. Cortese B, Ielasi A, Varricchio A, et al. Registro Absorb Italiano (BVS-RAI): an investigators-owned and-directed, open, prospective registry of consecutive patients treated with the Absorb™ BVS: study design. Cardiovasc Revasc Med 2015; 16: 340-3.
9. Gori T, Schulz E, Hink U, et al. Clinical, angiographic, functional, and imaging outcomes 12 months after implantation of drug-eluting bioresorbable vascular scaffolds in acute coronary syndromes. JACC Cardiovasc Interv 2015; 8: 770-7.
10. Rzeszutko Ł, Siudak Z, Włodarczak A, et al. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardiol Pol 2014; 72: 1394-409.
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-351.
12. Giuseppe G, Ortega-Paz L, Brugaletta S, et al. Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks. Postep Kardiol Inter 2015; 11: 161-9.
13. Ishibashi Y, Nakatani S, Sotomi Y et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv 2015; 8: 1715-26.
14. Wöhrle J, Naber C, Schmitz T, et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2015; 11: 149-56.
15. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10: 1144-53.
16. Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 2016; 387: 537-44.
17. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015; 36: 3332-42.
18. Sabaté M, Windecker S, Iniguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J 2016; 37: 229-40.
19. Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction). JACC Cardiovasc Interv 2015; 8: 189-97.
20. Abizaid A, Costa Jr. JR, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. Euro Intervention 2015; 10: 1396-401.
21. Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between Absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv 2015; 1: E10-5.
22. Mattesini A, Secco GG, Dall'Ara G, et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv 2014; 7: 741-50.
23. Caiazzo G, Kilic ID, Fabris E, et al. Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience? Int J Cardiol 2015; 15: 129-36.
24. Jaguszewski M, Ghadri JR, Zipponi M, et al. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios. Clin Res Cardiol 2015; 2: 124-35.
25. Robaei D, Back LM, Ooi SY, et al. Everolimus-eluting bioresorbable vascular scaffold implantation in real world and complex coronary disease: procedural and 30-day outcomes at two Australian centres. Heart Lung Circ 2015; 9: 854-9.